Ritemed Celecoxib Use In Pregnancy & Lactation

Pregnancy: Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see Contraindications and Pharmacology: Toxicology: Preclinical safety data under Actions).
Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy.
The potential for human risk in pregnancy is unknown, but cannot be excluded. Celecoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.
During the second or third trimester of pregnancy, NSAIDs including celecoxib may cause foetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. Such effects may occur shortly after treatment initiation and are usually reversible.
Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see Contraindications and Precautions). If a woman becomes pregnant during treatment, celecoxib should be discontinued.
Breastfeeding: Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma.
Administration of celecoxib to a limited number of lactating women has shown a very low transfer of celecoxib into breast milk.
Women who take celecoxib should not breastfeed.
Fertility: Based on the mechanism of action, the use of NSAIDs, including celecoxib, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.